NCT04515797

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single center study characterizing the experience of administration of 4 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.

Detailed description

The goal of this study is to determine if the administration of glecaprevir and pibrentasvir (G/P) for 4 weeks beginning in the immediate peri-transplant period prevents establishment of HCV infection in HCV negative recipients receiving transplanted kidneys from HCV RNA positive donors.

Conditions

• Kidney Failure
• Hepatitis C
• Kidney Disease, Chronic

Interventions

Type	Name	Description
DRUG	Glecaprevir and Pibrentasvir	4 weeks of treatment starting within 24 hrs of kidney transplant

Timeline

• Start date: 2021-05-01
• Primary completion: 2023-08-31
• Completion: 2023-08-31
• First posted: 2020-08-17
• Last updated: 2024-12-03
• Results posted: 2024-12-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study